33 research outputs found
5G-PPP Software Network Working Group:Network Applications: Opening up 5G and beyond networks 5G-PPP projects analysis
As part of the 5G-PPP Initiative, the Software Network Working Group prepared this white paper to demystify the concept of the Network Applications. In fact, the Network Application ecosystem is more than the introduction of new vertical applications that have interaction capabilities. It refers to the need for a separate middleware layer to simplify the implementation and deployment of vertical systems on a large scale. Specifically, third parties or network operators can contribute to Network Applications, depending on the level of interaction and trust. Different implementations have been conducted by the different projects considering different API types and different level of trust between the verticals and the owner of 5G platforms. In this paper, the different approaches considered by the projects are summarized. By analysing them, it appears three options of interaction between the verticals and the 5G platform owner: - aaS Model: it is the model where the vertical application consumes the Network Applications as a service. The vertical application deployed in the vertical service provider domain. It connects with the 3GPP network systems (EPS, 5GS) in one or more PLMN operator domain. - Hybrid: it is the model where the vertical instantiates a part of its Vertical App in the operator domain like the EDGE. The other part remains in the vertical domain. A similar approach has been followed in TS 23.286 related to the deployment of V2X server. - Coupled/Delegated: it is the model where the vertical delegates its app to the operator. The Network Applications will be composed and managed by the operator. This approach is the one followed in the platforms like 5G-EVE. In addition, the paper brings an analysis of the different API type deployed. It appears that the abstraction from network APIs to service APIs is necessary to hide the telco complexity making APIs easy to consume for verticals with no telco expertise and to adress data privacy requirements
Recommended from our members
A Scaleable and License Free 5G Internet of Radio Light Architecture for Services in Train Stations
In this paper we present a 5G Internet Radio-
Light (IoRL) architecture for underground train stations that
can be readily deployed because it utilizes unlicensed visible light
and millimeter wave part of the spectrum, which does not require
Mobile Network Operator (MNO) permission to deploy and
which is used to provide travelers with accurate location,
interaction, access to Internet and Cloud based Services, such as
high resolution video on a Tablet PC. The paper describes the
train station use cases and the IoRL architecture.European Commissio
A Scalable and License Free 5G Internet of Radio Light Architecture for Services in Homes & Businesses
In this paper we present a 5G Internet Radio-Light
(IoRL) architecture for homes that can be readily deployed
because it utilizes unlicensed visible light and millimeter wave
part of the spectrum, which does not require Mobile Network
Operator (MNO) permission to deploy and which is used to
provide inhabitants of houses with accurate location, interaction,
access to Internet and Cloud based services such as high
resolution video on a Tablet PC. The paper describes the home
use cases and the IoRL architecture.EU Horizon 202
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
Background Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8–13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05–6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50–75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life
Antihypertensive drugs and statins must be considered in arterial stiffness evaluation in patients with Alzheimer’s disease
Conceptual Evaluation of a 5G Network Slicing Technique for Emergency Communications and Preliminary Estimate of Energy Trade-Off
The definition of multiple slicing types in 5G has created a wide field for service innovation in communications. However, the advantages that network slicing has to offer remain to be fully exploited by today’s applications and users. An important area that can potentially benefit from 5G slicing is emergency communications for First Responders. The latter consists of heterogeneous teams, imposing different requirements on the connectivity network. In this paper, the RESPOND-A platform is presented, which provides First Responders with network-enabled tools on top of 5G on-scene planning, with enhanced service slicing capabilities tailored to emergency communications. Furthermore, a mapping of emergency services and communications to specific slice types is proposed to identify the current challenges in the field. Additionally, the proposed tentative mechanism is evaluated in terms of energy efficiency. Finally, the approach is summarized by discussing future steps in the convergence of 5G network slicing in various areas of emergency vertical applications